支气管动脉栓塞用于治疗血栓塞:永久性与临时性栓塞材料,一个单一中心的研究
Taninokuchi Tomassoni Makoto1, Perini Daniele2, Porta Francesco1
1Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni 15, Bologna, Italy.
CVIR endovascular
|May 7, 2025
概括
与临时药物相比,永久性栓塞剂显示出较高的长期成功率和较低的支气管动脉栓塞复发率. 这一发现支持它们在治疗血栓塞的使用,这两种类型的药物均观察到类似的安全性.
科学领域:
- 干预性放射学 干预性放射学
- 血管医学 血管医学
- 肺部医学 肺部医学
背景情况:
- 支气管动脉栓塞 (BAE) 是严重的血和肺出血的主要治疗方法.
- 栓塞剂的选择显著影响BAE的结果,但在最佳选择上没有共识.
- 这项研究评估了BAE的永久性与临时性栓塞剂.
研究的目的:
- 为了比较永久和临时栓塞剂在BAE的疗效,安全性和长期结果.
- 确定特定的栓塞材料是否在控制血栓塞的过程中具有优势.
- 评估与不同栓塞剂相关的复发率和并发症概况.
主要方法:
- 一项对94个BAE程序 (2006年7月至2024年5月) 的回顾性队列研究,涉及永久性 (线圈,颗粒,) 或临时性 (凝海绵) 剂.
- 包括需要干预的血栓塞患者;排除了非支气管原因或特定协议的患者.
- 评估的结果包括早期和晚期的临床成功 (分别在1周和6个月内没有复发) 和程序并发症.
主要成果:
- 在64%的程序中使用了永久性剂 (颗粒39%,粘合剂21%),而在35%的程序中使用了临时性剂 (凝海绵).
- 永久栓塞材料在临床结果中显示出统计学上显著的优势 (p=0.047).
- 在永久性和临时性药物之间没有发现安全性概况的显著差异.
结论:
- BAE是有效和安全的血控制,具有高的立即成功率.
- 与临时药物相比,永久性栓塞剂提供了优越的晚期临床成功和减少出血复发.
- 需要进一步的研究来验证这些发现,并巩固在BAE中最佳栓塞剂选择的证据.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
87
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
87
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
101
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
101
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
92
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
92